Journal of Gastroenterology

, Volume 46, Issue 11, pp 1335–1343 | Cite as

Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case–control study

  • Naoki Hiramatsu
  • Yuko Inoue
  • Tsugiko Oze
  • Nao Kurashige
  • Takayuki Yakushijin
  • Kiyoshi Mochizuki
  • Takuya Miyagi
  • Tomohide Tatsumi
  • Shinichi Kiso
  • Tatsuya Kanto
  • Akinori Kasahara
  • Tetsuo Takehara
  • Masahide Oshita
  • Eiji Mita
  • Hideki Hagiwara
  • Yoshiaki Inui
  • Kazuhiro Katayama
  • Shinji Tamura
  • Harumasa Yoshihara
  • Yasuharu Imai
  • Norio Hayashi
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

The antiviral effect of pegylated interferon (Peg-IFN) plus ribavirin combination therapy in chronic hepatitis C (CHC) patients with normal alanine aminotransferase (ALT) levels (N-ALT) has been reported to be equivalent to that for patients with elevated ALT levels (E-ALT). However, the actual antiviral effect in N-ALT patients remains obscure because efficacy can be overestimated in patients with an advantageous background.

Methods

In this study, 386 patients were extracted, for a matched case–control study, from 1320 CHC patients treated with Peg-IFN alpha-2b plus ribavirin combination therapy; 193 N-ALT patients [116 with hepatitis C virus genotype 1 (HCV-1), 77 with HCV genotype 2 (HCV-2)] were matched with 193 E-ALT patients by a propensity score method using the variables of age, sex, IFN treatment history, body mass index, and platelet counts.

Results

On multivariate analysis for sustained virological response (SVR) in N-ALT patients, younger age, low HCV RNA level at baseline, and HCV-2 were significant factors. The matched case–control study showed that the SVR rates of N-ALT patients were equivalent to those of E-ALT patients; at 49 and 40% in the HCV-1 group (P = 0.146), and 78 and 81% in the HCV-2 group (P = 0.691). However, in N-ALT patients with non-SVR, approximately 40% showed ALT elevation at 24 weeks post-treatment.

Conclusion

Our findings indicate that the antiviral effect of Peg-IFN plus ribavirin therapy in N-ALT patients is comparable to that for E-ALT patients irrespective of their advantageous background; however, the application of this therapy for N-ALT patients, especially for those with HCV-1, should be considered carefully.

Keywords

Hepatitis C virus Normal alanine aminotransferase Pegylated interferon plus ribavirin combination therapy Propensity score method Matched case–control study 

Notes

Acknowledgments

Other institutions and participants in the Osaka Liver Forum are: Higashi Osaka General Hospital, S. Iio; Sumitomo Hospital, A. Yamada; Osaka General Medical Center, A. Inoue; Toyonaka Municipal Hospital, M. Inada; National Hospital Organization Osaka Minami Medical Center, T. Hijioka; Yao Municipal Hospital, H. Fukui; Kinki Central Hospital of Mutual Aid Association of Public School Teachers, E. Hayashi; Osaka Koseinenkin Hospital, T. Ito; Itami City Hospital, T. Kashihara; Suita Municipal Hospital, T. Nagase; Ashiya Municipal Hospital, K. Kiriyama; Saiseikai Senri Hospital, K. Suzuki; NTT West Osaka Hospital, A. Kaneko; National Hospital Organization Minami Wakayama Medical Center, M. Kato; Otemae Hospital, Y. Doi; Kano General Hospital, S. Kubota; Nishinomiya Municipal Central Hospital, H. Ogawa; and Osaka Kaisei Hospital, N. Imaizumi. This work was supported by a Grant-in-Aid for Research on Hepatitis and BSE from the Ministry of Health, Labour and Welfare of Japan, and Scientific Research from the Ministry of Education, Science, and Culture of Japan. All authors have no financial relationship relevant to this study to disclose.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology. 2001;34:1000–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Okanoue T, Makiyama A, Nakayama M, Sumida Y, Mitsuyoshi H, Nakajima T, et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol. 2005;43:599–605.PubMedCrossRefGoogle Scholar
  3. 3.
    Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology. 2000;118:760–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Puoti C, Castellacci R, Montagnese F, Zaltron S, Stornaiuolo G, Bergami N, et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol. 2002;37:117–23.PubMedCrossRefGoogle Scholar
  5. 5.
    Tsuji K, Yamasaki K, Yamanishi M, Kawakami M, Shirahama S. Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: a 10-year follow-up study. J Gastroenterol Hepatol. 2001;16:536–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Sangiovanni A, Morales R, Spinzi G, Rumi M, Casiraghi A, Ceriani R, et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology. 1998;27:853–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Serfaty L, Chazouilleres O, Pawlotsky JM, Andreani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology. 1996;110:291–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Shiffman ML, Stewart CA, Hofmann CM, Contos MJ, Luketic VA, Sterling RK, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis. 2000;182:1595–601.PubMedCrossRefGoogle Scholar
  9. 9.
    Tassopoulos NC. Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol. 1999;31(Suppl 1):193–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004;127:1724–32.PubMedCrossRefGoogle Scholar
  11. 11.
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Gholson CF, Morgan K, Catinis G, Favrot D, Taylor B, Gonzalez E, et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol. 1997;92:1788–92.PubMedGoogle Scholar
  13. 13.
    Herve S, Savoye G, Riachi G, Hellot MF, Goria O, Lerebours E, et al. Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity? Eur J Gastroenterol Hepatol. 2001;13:495–500.PubMedCrossRefGoogle Scholar
  14. 14.
    Puoti C, Bellis L, Galossi A, Guarisco R, Nicodemo S, Spilabotti L, et al. Antiviral treatment of HCV carriers with persistently normal ALT levels. Mini Rev Med Chem. 2008;8:150–2.PubMedCrossRefGoogle Scholar
  15. 15.
    Puoti C, Bellis L, Martellino F, Guarisco R, Dell’ Unto O, Durola L, et al. Chronic hepatitis C and ‘normal’ ALT levels: treat the disease not the test. J Hepatol. 2005;43:534–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Puoti C, Castellacci R, Montagnese F. Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? Dig Liver Dis. 2000;32:634–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 1997;26:1393–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.PubMedCrossRefGoogle Scholar
  19. 19.
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.PubMedGoogle Scholar
  20. 20.
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.PubMedCrossRefGoogle Scholar
  21. 21.
    Puoti C, Pellicelli AM, Romano M, Mecenate F, Guarisco R, Barbarini G, et al. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study. Liver Int. 2009;29:1479–84.PubMedCrossRefGoogle Scholar
  22. 22.
    Deuffic-Burban S, Babany G, Lonjon-Domanec I, Deltenre P, Canva-Delcambre V, Dharancy S, et al. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology. 2009;50:1351–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.PubMedCrossRefGoogle Scholar
  24. 24.
    Okanoue T, Itoh Y, Minami M, Hashimoto H, Yasui K, Yotsuyanagi H, et al. Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatol Res. 2008;38:27–36.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Naoki Hiramatsu
    • 1
  • Yuko Inoue
    • 1
  • Tsugiko Oze
    • 1
  • Nao Kurashige
    • 1
  • Takayuki Yakushijin
    • 1
  • Kiyoshi Mochizuki
    • 1
  • Takuya Miyagi
    • 1
  • Tomohide Tatsumi
    • 1
  • Shinichi Kiso
    • 1
  • Tatsuya Kanto
    • 1
  • Akinori Kasahara
    • 1
  • Tetsuo Takehara
    • 1
  • Masahide Oshita
    • 2
  • Eiji Mita
    • 3
  • Hideki Hagiwara
    • 4
  • Yoshiaki Inui
    • 5
  • Kazuhiro Katayama
    • 6
  • Shinji Tamura
    • 7
  • Harumasa Yoshihara
    • 8
  • Yasuharu Imai
    • 9
  • Norio Hayashi
    • 4
  1. 1.Department of Gastroenterology and HepatologyOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Osaka Police HospitalOsakaJapan
  3. 3.National Hospital Organization Osaka National HospitalOsakaJapan
  4. 4.Kansai Rosai HospitalAmagasakiJapan
  5. 5.Hyogo Prefectural Nishinomiya HospitalNishinomiyaJapan
  6. 6.Osaka Medical Center for Cancer and Cardiovascular DiseasesOsakaJapan
  7. 7.Minoh City HospitalMinohJapan
  8. 8.Osaka Rosai HospitalSakaiJapan
  9. 9.Ikeda Municipal HospitalIkedaJapan

Personalised recommendations